Genome-wide association studies show that HIF-1α and its target genes are upregulated in breast cancer, and clinical data suggest that, compared to hormone responsive and HER-2 positive breast cancers, TNBCs are particularly enriched for HIF-1 and its target genes (Ma et al., 2022). The gene discussed is ERBB2; the disease is breast carcinoma.